

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

Brilliant Violet 750(TM) anti-mouse/human CD11b

RRID:AB_2810328

Type: Antibody

Proper Citation

BioLegend Cat# 101267, RRID:AB_2810328

Antibody Information

URL: http://antibodyregistry.org/AB_2810328

Proper Citation: BioLegend Cat# 101267, RRID:AB_2810328

Target Antigen: CD11b

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 750(TM) anti-mouse/human CD11b

Description: This monoclonal targets CD11b

Target Organism: cynomolgus, mouse, rhesus, human

Clone ID: Clone M1/70

Antibody ID: AB_2810328

Vendor: BioLegend

Catalog Number: 101267

Record Creation Time: 20231110T032647+0000

Record Last Update: 20260829T152154+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 750(TM) anti-mouse/human CD11b.

No alerts have been found for Brilliant Violet 750(TM) anti-mouse/human CD11b.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Huang X, et al. (2026) Opposing functions of distinct regulatory T cell subsets in colorectal cancer. *Immunity*, 59(1), 145.

Triana-Martinez F, et al. (2026) p16High immune cells control disease tolerance as a defense and health span-extending strategy. *Immunity*, 59(6), 1633.

Izzati FN, et al. (2025) Presentation of immunoregulatory sialoglycans on T cells is divergent between mice and humans. *Cell reports*, 44(7), 115933.

Koliesnik I, et al. (2025) An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy. *Cell reports*, 45(1), 116757.

Whiteley AE, et al. (2024) Breast cancer exploits neural signaling pathways for bone-to-meninges metastasis. *Science (New York, N.Y.)*, 384(6702), eadh5548.

Mannion J, et al. (2024) A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death. *Immunity*, 57(7), 1514.

Dikiy S, et al. (2021) A distal Foxp3 enhancer enables interleukin-2 dependent thymic Treg cell lineage commitment for robust immune tolerance. *Immunity*, 54(5), 931.

Uzhachenko RV, et al. (2021) Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T??cells into mammary tumors. *Cell reports*, 35(1), 108944.